3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Head & Neck
1
Gynecologic
1
Conditions
Breast Neoplasms
33
Breast Diseases
3
Neoplasms by Site
2
Neoplasms
2
Neoplasm Metastasis
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Neoplasms, Male
2
Advanced Breast Cancer
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sexual Dysfunctions, Psychological
1
Ovarian Neoplasms
1
Low Grade Serous Ovarian Cancer
1
Locoregional Recurrence
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
HER2 Negative Breast Cancer
1
Endometrial Neoplasms
1
Carcinoma, Lobular
1
Carcinoma, Ductal, Breast
1
Breast Neoplasm Female
1
Breast Carcinoma In Situ
1
Anatomic Stage III Breast Cancer AJCC v8
1
Anatomic Stage II Breast Cancer AJCC v8
1
Advanced Breast Carcinoma
1
Interventions
durvalumab
3
abemaciclib
3
Fulvestrant
3
Cisplatin
3
ribociclib
2
pembrolizumab
2
palbociclib
2
Pemetrexed
2
Nivolumab
2
Letrozole
2
Carboplatin
2
Bevacizumab
2
Anastrozole
2
130-nm albumin-bound paclitaxel
2
selpercatinib
1
selinexor
1
repotrectinib
1
relatlimab
1
relacorilant
1
olaparib
1
gallium 68 PSMA-11
1
exemestane
1
enfortumab vedotin
1
elacestrant
1
darolutamide
1
cemiplimab
1
atezolizumab
1
Tamoxifen
1
Sunitinib
1
STX-478
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
Anastrozole
×
90 days
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled